Advertisement

Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C

  • Marlene W. Modi
  • Matthew W. Lamb
  • Mari Shiomi
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 519)

Keywords

Chronic Hepatitis Sustained Virological Response Vinyl Sulfone Unmodified Protein Succinimidyl Carbonate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sharara, A.I., Hunt, C.M., et al., 1996, Hepatitis C. Ann Intern Med 125:658–68.PubMedGoogle Scholar
  2. 2.
    Koziel, M.J., 1996, Immunology of viral hepatitis. Am J Med 100:98–109.CrossRefPubMedGoogle Scholar
  3. 3.
    Kiyasu, P.K. and Caldwell, S.H., 1993, Diagnosis and treatment of the major hepatotropic viruses. Am J Med Sci 306: 248–61.PubMedGoogle Scholar
  4. 4.
    Iwarson, S., Norkraus, G. et al., 1995, Hepatitis C: natural history of a unique infection. Clin Infect Dis 20: 1361–70.PubMedGoogle Scholar
  5. 5.
    Alter, M., 1997, Epidemiology of hepatitis C. Hepatology 26:(3 Suppl 1): 625–655.Google Scholar
  6. 6.
    Davis, G.L., 2000, Current therapy for chronic hepatitis C. Gastroenterol 118(Suppl 1): S104–S114.Google Scholar
  7. 7.
    Lawrence, S.P., 2000, Advances in the treatment of hepatitis C. In Advances in Internal Medicine. Mosby, St. Louis.Google Scholar
  8. 8.
    Hoofnagle, J.H. and di Bisceglie, A.M., 1997, The treatment of chronic viral hepatitis. N Engl J Med 336: 347–56.CrossRefPubMedGoogle Scholar
  9. 9.
    McHutchinson, J.G., Gordon, S.C., et. al., 1998, Interferon alfa-2b or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485–92.Google Scholar
  10. 10.
    Wills, R.J., 1990, Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19: 390–399.PubMedGoogle Scholar
  11. 11.
    Bocci, V., Pacini, A. et. al., 1981, Renal filtration, absorption and catabolism of human alpha interferon. J Interferon Res 1: 347–52.PubMedGoogle Scholar
  12. 12.
    Zeuzem, S., Herrmann, E. et. al., 2001, Viral kinetics with chronic hepatitis C patients treated with standard or peginterferon alfa-2a. Gastroenterol 120: 1438–1447.Google Scholar
  13. 13.
    Lam, N.P. Neumann, A.U. et. al., 1997, Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26: 226–31.PubMedGoogle Scholar
  14. 14.
    Zhi, J., Teller, S.B. et al., 1995, Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2b given by subcutaneous injection in healthy male volunteers. J Clin Pharmacol 35: 281–4.PubMedGoogle Scholar
  15. 15.
    Harris, J.M., Martin, N.E., et. al., 2001, Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539–51.PubMedGoogle Scholar
  16. 16.
    Yamaoka, T., Tabata, Y., et. al., 1994, Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm Sci 83: 601–6.PubMedGoogle Scholar
  17. 17.
    Fung, W.-J., Porter, J.E., et. al., 1997, Strategies for the preparation and characterization of polyethylene glycol vinyl sulfone. Polymers Preprint: 565–66.Google Scholar
  18. 18.
    Nieforth, K.A., Nadeau, R., et. al., 1996, Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 59: 636–46.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu, Z.-X., Patel, I., et al., 1998, Single-dose safety, tolerability and pharmacokinetics of PEG-FIN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 28(Suppl): 702.Google Scholar
  20. 20.
    Bailon, P., Palleroni, A., et al., 2001, Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem 12: 195–202.CrossRefGoogle Scholar
  21. 21.
    Bailon, P., Spence, C., et al., 1999, Pharmacokinetic properties of five polyethylene glycol conjugates of interferon alfa-2a. Antiviral Therapy 4(Suppl 4): 27.Google Scholar
  22. 22.
    Harris, N.J., Veronese, F.M., et al., 1999, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces. US Patent & Trademark Office, USA.Google Scholar
  23. 23.
    Algranati, N.E., Sy, S., et. al., 1999, A branched methoxy 40 kDa, polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of PEG-IFN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 40: 190.Google Scholar
  24. 24.
    Modi, M.W., Fried, M.W., et. al., 2000, The pharmacokinetic behavior of pegylated (40 kDa) interferon alfa-2a (PEGASYS) in chronic hepatitis patients after multiple dosing. Hepatology 32 (4 Pt 2 of 2): 394A.Google Scholar
  25. 25.
    Zeuzem, S., Feinman, S.V., et al., 2000, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Heathcote, E.J., Shiftman, M.J., et. al., 2000, Peginterferon alfa-2a in patieints with chronic hepatitis C and cirrhosis. N Engl J Med 345: 1673–80.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Marlene W. Modi
    • 1
  • Matthew W. Lamb
    • 1
  • Mari Shiomi
    • 2
  1. 1.Department of Clinical PharmacologyHoffmann-La Roche, Inc.NutleyUSA
  2. 2.Clinical Pharmacology GroupNippon Roche K.K.TokyoJapan

Personalised recommendations